Stroke treatment with urokinase in real-world settings
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study looks at how well the clot-busting drug urokinase works for treating acute ischemic stroke in everyday medical practice. It may help if you have had a stroke and are eligible for clot-dissolving medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a new, sudden stroke that causes weakness or trouble speaking, and brain scans show it is caused by a clot, not bleeding.
- This is your first stroke, or any previous stroke left you with no major disability (able to do daily activities on your own).
- Your doctor decides you can safely receive a clot-busting drug like urokinase or alteplase.
- You agree to take part and sign a consent form (or a family member or legal representative can agree for you).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
This trial tests whether the clot-busting drug urokinase can help people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to dissolve the clot and improve recovery, as long as treatment starts within 6 hours of the first symptoms.
This trial tests whether adding a drug called human urinary kallidinogenase to standard clot-busting therapy with reteplase improves outcomes for people having a first or recurrent ischemic stroke. It is designed for patients who can start treatment within 4.5 hours of symptoms and have moderate stroke severity.
This trial tests a clot-dissolving medication (pro-urokinase) for people with recent strokes in the back of the brain. You would be treated 4.5 to 9 hours after symptoms start, which is beyond the typical treatment window, using special MRI patterns to identify patients most likely to benefit.
This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.